Efficacy and Safety of TAF for 48 Weeks in HBeAg Positive CHB Patients
Latest Information Update: 28 Dec 2023
At a glance
- Drugs Tenofovir alafenamide (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 14 Nov 2023 Results assessing efficacy and safety of Tenofovir-alafenamide, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
- 12 Mar 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 12 Mar 2023 Planned primary completion date changed from 30 Aug 2022 to 27 Oct 2023.